Mountain Valley MD (MVMD. C) is biotech company centred around the implementation and licensing of its patented Quicksome™ oral delivery technologies across the global nutraceutical, vaccine and pharmaceutical landscape.
MVMD's underlying Quicksome™ technology has been in development since 2010, initially incorporated into several commercial dietary supplement products. They have 14 patents in our patent portfolio, 12 extensions and have filed over a dozen provisional patents with respect to our Quicksome™ technology
Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective oral dissolving product formats.
Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable injection or liquid application of poorly soluble drugs to enhance bioavailability orally and transdermally.
https://www.mountainvalleymd.com/
